Le Nguyen-Ngoc-Quynh, Ngoc Can-Thi-Bich, Duong Dang-Anh, Ha Dang-Thi, Thoa Ta-Thi, Binh Nguyen-Thanh, Dung Vu-Chi, Dien Tran-Minh, Tung Cao-Viet
{"title":"First bone marrow transplantation for mucopolysaccharidosis type I in Vietnam: a case report.","authors":"Le Nguyen-Ngoc-Quynh, Ngoc Can-Thi-Bich, Duong Dang-Anh, Ha Dang-Thi, Thoa Ta-Thi, Binh Nguyen-Thanh, Dung Vu-Chi, Dien Tran-Minh, Tung Cao-Viet","doi":"10.1177/26330040261469199","DOIUrl":null,"url":null,"abstract":"<p><p>Mucopolysaccharidosis type I (MPS-I) is an inherited lysosomal storage disorder characterized by alpha-L-iduronidase deficiency, leading to progressive multi-organ damage and fatal complications. Early treatment is crucial to improve outcomes, particularly in patients with severe phenotypes. We present the first case of successful allogeneic bone marrow transplantation (BMT) for MPS-I in Vietnam. A 10-month-old girl experienced coarse facial features, congenital dermal melanocytosis spots, kyphoscoliosis developmental delay. Laboratory analyses revealed reduced alpha-L-iduronidase activity and elevated urinary glycosaminoglycans, genetic mutations identified two heterozygous mutations in the <i>IDUA</i> gene, confirmed the diagnosis of MPS-I. At 3 years old, she underwent allogeneic BMT from an HLA-matched sibling donor following conditioning regimen with busulfan, cyclophosphamide, antithymocyte globulin. Neutrophil engraftment was achieved on day +24, and platelet engrafted on day +32. The post-transplant course was complicated by respiratory deterioration requiring 5 days of mechanical ventilation, which was promptly managed and resolved. No graft-versus-host disease occurred. Post-transplant chimerism showed 95.77% donor-derived cells on day +30 and remained stable at 100% from 2 months. The patient demonstrated improvement in clinical symptoms, accompanied by alpha-L-iduronidase activity returned to normal range, urinary glycosaminoglycan levels decreased and remained stable during follow-up. At 12 months, she demonstrated complete immune reconstitution. This case suggests that allogeneic BMT may be a therapeutic approach for patients with MPS-I in resource-limited settings.</p>","PeriodicalId":75218,"journal":{"name":"Therapeutic advances in rare disease","volume":"7 ","pages":"26330040261469199"},"PeriodicalIF":0.0000,"publicationDate":"2026-08-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13434929/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Therapeutic advances in rare disease","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1177/26330040261469199","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/1/1 0:00:00","PubModel":"eCollection","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Mucopolysaccharidosis type I (MPS-I) is an inherited lysosomal storage disorder characterized by alpha-L-iduronidase deficiency, leading to progressive multi-organ damage and fatal complications. Early treatment is crucial to improve outcomes, particularly in patients with severe phenotypes. We present the first case of successful allogeneic bone marrow transplantation (BMT) for MPS-I in Vietnam. A 10-month-old girl experienced coarse facial features, congenital dermal melanocytosis spots, kyphoscoliosis developmental delay. Laboratory analyses revealed reduced alpha-L-iduronidase activity and elevated urinary glycosaminoglycans, genetic mutations identified two heterozygous mutations in the IDUA gene, confirmed the diagnosis of MPS-I. At 3 years old, she underwent allogeneic BMT from an HLA-matched sibling donor following conditioning regimen with busulfan, cyclophosphamide, antithymocyte globulin. Neutrophil engraftment was achieved on day +24, and platelet engrafted on day +32. The post-transplant course was complicated by respiratory deterioration requiring 5 days of mechanical ventilation, which was promptly managed and resolved. No graft-versus-host disease occurred. Post-transplant chimerism showed 95.77% donor-derived cells on day +30 and remained stable at 100% from 2 months. The patient demonstrated improvement in clinical symptoms, accompanied by alpha-L-iduronidase activity returned to normal range, urinary glycosaminoglycan levels decreased and remained stable during follow-up. At 12 months, she demonstrated complete immune reconstitution. This case suggests that allogeneic BMT may be a therapeutic approach for patients with MPS-I in resource-limited settings.
粘多糖病I型(MPS-I)是一种遗传性溶酶体贮积性疾病,以α - l -伊杜糖醛酸酶缺乏为特征,可导致进行性多器官损害和致命并发症。早期治疗对于改善预后至关重要,特别是对于严重表型的患者。我们提出了首例成功的异基因骨髓移植(BMT)的MPS-I在越南。一个10个月大的女孩面部特征粗糙,先天性皮肤黑素细胞增多斑,脊柱后凸发育迟缓。实验室分析显示α - l -iduronidase活性降低,尿糖胺聚糖升高,基因突变鉴定出IDUA基因的两个杂合突变,证实了MPS-I的诊断。在3岁时,她接受了来自hla匹配的兄弟姐妹供体的异基因BMT治疗,治疗方案为布苏凡、环磷酰胺、抗胸腺细胞球蛋白。中性粒细胞移植于第24天,血小板移植于第32天。移植后的过程中出现呼吸恶化,需要5天的机械通气,这是及时管理和解决。无移植物抗宿主病发生。移植后第30天嵌合率为95.77%,2个月后稳定在100%。患者临床症状改善,α - l -伊杜糖醛酸酶活性恢复正常,尿糖胺聚糖水平下降,随访期间保持稳定。12个月时,她表现出完全的免疫重建。该病例提示同种异体骨髓移植可能是资源有限的MPS-I患者的一种治疗方法。